{"prompt": "['MC1575', '40', 'Amendment 2', '10.6232', \"Any death more than 30 days after the patient's last study\", 'treatment or procedure that is felt to be at least possibly', 'treatment related must also be submitted as a Grade 5 AE,', 'with a CTCAE type and attribution assigned.', '10.7', 'Late Occurring Adverse Events', 'Refer to the instructions in the Forms Packet (or electronic data entry screens, as', 'applicable) regarding the submission of late occurring AEs following completion of the', 'Active Monitoring Phase (i.e., compliance with Test Schedule in Section 4.0).', '10.8', '[Insert industry partner name] Additional Event Reporting Instructions', 'Insert any additional language requested by industry partners in this section.', '11.0', 'TREATMENT EVALUATION', 'NOTE: This study uses protocol RECIST v1.1 template dated 2/16/2011. See the footnote for the', 'table regarding measureable disease in Section 11.44, as it pertains to data collection and', 'analysis.', 'Response and progression will be evaluated in this study using the new international criteria', 'proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guidelines', '(version 1. )(Eisenhauer, Therasse et al. 2009). Changes in the largest diameter (unidimensional', 'measurement) of the tumor lesions and the short axis measurements in the case of lymph nodes', 'are used in the RECIST guideline.', '11.1', 'Schedule of Evaluations', 'For the purposes of this study, patients should be reevaluated every 8 weeks for the first', 'year and then every 12 weeks after Year 1.', '11.2', 'Definitions of Measurable and Non-Measurable Disease', '11.21 Measurable Disease', '11.211 A non-nodal lesion is considered measurable if its longest diameter can', 'be accurately measured as >1.0 cm with CT scan, CT component of a', 'PET/CT, or MRI.', '11.212 A malignant lymph node is considered measurable if its short axis is', '>1.5 cm when assessed by CT scan (CT scan slice thickness', 'recommended to be no greater than 5 mm).', 'NOTE:', 'Tumor lesions in a previously irradiated area are considered measurable disease', 'under the following conditions:', 'If they have progressed at screening evaluation', '11.22 Non-Measurable Disease', 'All other lesions (or sites of disease) are considered non-measurable disease,', 'including pathological nodes (those with a short axis >1.0 to <1.5 cm). Bone', 'lesions, leptomeningeal disease, ascites, pleural/pericardial effusions,', 'lymphangitis cutis/pulmonis, inflammatory breast disease, and abdominal masses', '(not followed by CT or MRI), are considered as non-measurable as well.', 'Note: \"Cystic lesions\\' thought to represent cystic metastases can be considered as', 'measurable lesions, if they meet the definition of measurability described above.', 'Protocol Version Date: :16Aug2018']['MC1575', '41', 'Amendment 2', 'However, if non-cystic lesions are present in the same patient, these are preferred', 'for selection as target lesions. In addition, lymph nodes that have a short axis', '<1.0 cm are considered non- pathological (i.e., normal) and should not be', 'recorded or followed.', '11.3', 'Guidelines for Evaluation of Measurable Disease', '11.31 Measurement Methods:', 'All measurements should be recorded in metric notation (i.e., decimal', 'fractions of centimeters) using a ruler or calipers.', 'The same method of assessment and the same technique must be used to', 'characterize each identified and reported lesion at baseline and during', 'follow-up. For patients having only lesions measuring at least 1 cm to less', 'than 2 cm must use CT imaging for both pre- and post-treatment tumor', 'assessments.', 'Imaging-based evaluation is preferred to evaluation by clinical examination', 'when both methods have been used at the same evaluation to assess the', 'antitumor effect of a treatment.', '11.32 Acceptable Modalities for Measurable Disease:', 'Conventional CT and MRI: This guideline has defined measurability of', 'lesions on CT scan based on the assumption that CT slice thickness is 5 mm', 'or less. If CT scans have slice thickness greater than 5 mm, the minimum', 'size for a measurable lesion should be twice the slice thickness.', 'As with CT, if an MRI is performed, the technical specifications of the', 'scanning sequences used should be optimized for the evaluation of the type', 'and site of disease. The lesions should be measured on the same pulse', 'sequence. Ideally, the same type of scanner should be used and the image', 'acquisition protocol should be followed as closely as possible to prior scans.', 'Body scans should be performed with breath-hold scanning techniques, if', 'possible.', 'PET-CT: If the site can document that the CT performed as part of a PET-CT', 'is of identical diagnostic quality to a diagnostic CT (with IV and oral', 'contrast), then the CT portion of the PET-CT can be used for RECIST', 'measurements and can be used interchangeably with conventional CT in', 'accurately measuring cancer lesions over time.', 'FDG-PET: FDG-PET scanning is allowed to complement CT scanning in', \"assessment of progressive disease [PD] and particularly possible 'new'\", 'disease. A \"positive\\' FDG-PET scanned lesion is defined as one which is', 'FDG avid with an update greater than twice that of the surrounding tissue on', 'the attenuation corrected image; otherwise, an FDG-PET scanned lesion is', 'considered \"negative. New lesions on the basis of FDG-PET imaging can be', 'identified according to the following algorithm:', 'a.', 'Negative FDG-PET at baseline with a positive FDG-PET at follow-up is', 'a sign of PD based on a new lesion.', 'b.', 'No FDG-PET at baseline and a positive FDG-PET at follow-up:', 'i.', 'If the positive FDG-PET at follow-up corresponds to a new site of', 'disease confirmed by CT, this is PD.', 'Protocol Version Date:16Aug2018']\n\n###\n\n", "completion": "END"}